ASTRAZENECA PLC
No SEC Form 4 filings for $AZN in the last 30 days.
See all $AZN insider activity →Investing.com reports Morgan Stanley analysts visited National Resilience’s Ohio facilities near Cincinnati. The private contract manufacturer serves biopharma clients including Eli Lilly (LLY) and AstraZeneca (AZN), producing Tirzepatide auto-injectors and vials. National Resilience plans to invest over $400 million from 2023-2028 to expand fill-finish capacity and workforce.
The U.S. Federal Circuit affirmed a Delaware ruling that invalidated Wyeth LLC’s cancer treatment patents against AstraZeneca, removing an infringement damages award of about $107.5 million. The court found the patents lacked enablement under 35 U.S.C. §112(a), citing insufficient guidance to translate in vitro data into therapeutically effective human daily dosing, under the Amgen framework.
Reuters reported AstraZeneca (AZN) held merger talks with U.S. rival Bristol-Myers Squibb (BMY). AZN shares fell as much as 9% on Monday, while BMY rose up to 6% before easing. Neither company confirmed. The firms cited include a potential $400B combined value, with investors questioning AstraZeneca’s need for a deal and BMY’s patent-expiry pressures.
Over the past 7 days, alphai's AI scored 40 news stories mentioning AZN (ASTRAZENECA PLC). Coverage has skewed bullish: 17 bullish, 20 neutral, and 3 bearish.
Recent AZN coverage spans mergers & acquisitions, regulation and earnings.
AZN being a client of an expanding CDMO suggests ongoing outsourced manufacturing demand, but no incremental AZN-specific update is provided.
Ruling reduces AstraZeneca’s patent-legal overhang tied to the asserted claims, but does not change Tagrisso’s clinical profile.
Rumor-driven selloff suggests near-term downside risk to AZN sentiment and deal optionality, pending confirmation or denial.
Potential AZN-BMY deal talks raise M&A optionality and deal-risk, but the article provides no confirmed terms or timing.
Near-term downside bias for AZN tied to defensive-sector underperformance rather than company-specific fundamentals.
alphai scores every news story that mentions AZN with an AI model for sentiment and relevance, and aggregates insider trades from ASTRAZENECA PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Investing.com reports Morgan Stanley analysts visited National Resilience’s Ohio facilities near Cincinnati. The private contract manufacturer serves biopharma clients including Eli Lilly (LLY) and AstraZeneca (AZN), producing Tirzepatide auto-injectors and vials. National Resilience plans to invest over $400 million from 2023-2028 to expand fill-finish capacity and workforce.
3 min readThe U.S. Federal Circuit affirmed a Delaware ruling that invalidated Wyeth LLC’s cancer treatment patents against AstraZeneca, removing an infringement damages award of about $107.5 million. The court found the patents lacked enablement under 35 U.S.C. §112(a), citing insufficient guidance to translate in vitro data into therapeutically effective human daily dosing, under the Amgen framework.
6 min readReuters reported AstraZeneca (AZN) held merger talks with U.S. rival Bristol-Myers Squibb (BMY). AZN shares fell as much as 9% on Monday, while BMY rose up to 6% before easing. Neither company confirmed. The firms cited include a potential $400B combined value, with investors questioning AstraZeneca’s need for a deal and BMY’s patent-expiry pressures.
6 min readFinancial Times reported that AstraZeneca held talks with Bristol-Myers Squibb through spring and summer about a potential acquisition. By early August, discussions reportedly focused on a mostly stock-based deal in which AstraZeneca would buy Bristol-Myers for a premium.
2 min readThe FTSE 100 was little changed on Tuesday, lagging other European markets. Defensive stocks fell, including AstraZeneca (-1%), GSK (-1.5%) and Unilever (-0.6%), while energy rose, with Shell (+1.4%) and BP (+1.8%). Oil gains eased after renewed Middle East agreement hopes. InterContinental Hotels Group fell over 2%, and Bellway warned on outlook. UK retail sales rose 1.3% y/y, and Barclays cited consumer spending up 2% y/y.
2 min readAstraZeneca (NYSE:AZN) reported Q2 core EPS of $2.63, above analysts’ $2.48, and reiterated its goal of $80 billion annual revenue by 2030. The quarter also included setbacks, including Ultomiris missing a late-stage goal and prior trial failures. Investors are weighing pipeline confidence after AZN shares fell on Wainua’s trial failure.
6 min readAstraZeneca and Bristol Myers Squibb held preliminary talks about a potential combination valued near $400 billion, according to a person familiar with the situation cited by Reuters. The report cites possible US antitrust scrutiny under President Trump. AstraZeneca’s Q2 results showed strong cancer and rare-disease demand, while BMS raised its full-year forecast.
6 min readAstraZeneca Pharma India Limited approved a dividend of ₹36 per equity share at its 47th AGM on Aug 10, 2026, according to the company’s exchange disclosure. The resolution was also tied to adoption of financial statements for the year ended Mar 31, 2026. On Aug 11 at 9:27 AM IST, shares traded at ₹8,026.50, down 0.78% from the prior close.
3 min readAstraZeneca reported Q2 results that beat Wall Street expectations and reiterated full-year 2026 guidance. Core EPS rose 18% to $2.63 and revenue was $15.38 billion. Oncology and Rare Disease growth offset a 15% decline in CVRM from Farxiga LOE and China VBP cuts. A Phase 3 Ultomiris study failed its primary endpoint. AZN aims for $80 billion revenue by 2030.
6 min readA U.S. District Court dismissed three complaints by AbbVie, AstraZeneca and PhRMA challenging a 2025 South Dakota amendment requiring manufacturers to deliver generic drugs directly to local healthcare providers. The Attorney General’s office said the law limits manufacturers’ control over contract terms for discounted drugs under the federal 340B Program, especially for rural and underserved patients.
4 min read
